Latest Commercialization News

Orion Minerals has locked in a US$250 million prepayment facility with Glencore to fund key developments at its Prieska Copper Zinc Project, marking a pivotal step toward production in South Africa.

Paradigm Biopharmaceuticals has entered a binding agreement with AVet Health to co-develop and license a novel oral therapy for veterinary osteoarthritis in Australia and New Zealand, unlocking new market potential while advancing its human clinical trials.

Algorae Pharmaceuticals has secured a key Licence & Supply Agreement with Cadila Pharmaceuticals to commercialise two generic cardiovascular and metabolic medicines in Australia and New Zealand, broadening its therapeutic reach beyond oncology.

Memphasys Limited has secured Therapeutic Goods Administration approval for its Felix™ System two months ahead of schedule, enabling immediate commercial sales and clinical use in Australia.

Condor Energy has unveiled a significant upgrade to its offshore Peru portfolio with the addition of the Raya West prospect, pushing the Greater Raya area’s prospective oil resources beyond 900 million barrels. This milestone enhances Condor’s position as a major player in the Tumbes Basin exploration landscape.

A single exploration name blew the doors off the leaderboard, while two well-known uranium plays and a Nevada explorer sank hard. Behind the noise: deals got closer to completion, big raisings reset prices, and several “good news” gaps didn’t survive the week.

Credit stocks swung hard, with Credit Corp sliding despite steady profits and a busy acquisition agenda. Payments and capital management stories did the heavy lifting elsewhere, from Klevo’s Mastercard milestones to Regal’s buy-back.

A single drill program in WA delivered a once-a-year spike, while several small caps fell hard after reopening with price gaps. This week also saw big money raised for gold and uranium builds, and a run of resource upgrades across critical minerals.

A single diagnostics update sparked a breakout week, while a handful of biotech names sold off hard despite busy newsflow. Capital raisings, takeover steps and US market pushes kept healthcare in motion heading into mid-February milestones.

A volatile week for ASX tech saw a steep sell-off in freight software, while defence AI and RegTech contract wins pulled buyers back into smaller names. Big corporate actions kept attention on what’s real: signed deals, cash timelines, and who pays whom, and when.

Osteopore Limited has successfully raised the entire $5 million from the first tranche of its $20 million convertible notes issuance, securing funds to support ongoing operations and future growth.

Nimy Resources has dispatched its first shipment of high-grade gallium mineralised test material from Western Australia to the United States, marking a key step in developing a secure Western supply chain for this critical mineral. The collaboration with M2i Global aims to identify optimal processing routes to support U.S. defence and semiconductor industries.